GE HealthCare’s recently acquired MIM Software division has secured an FDA clearance for a tool to help quantify the density ...

A CareSouth Carolina patient is among the first in the United States to receive a groundbreaking treatment aimed at slowing ...

Eli Lilly and Company (LLY), one of the world’s largest pharmaceutical companies, boasts a diversified product profile. Lilly has consistently reported strong revenues and profits. It has seen ...

Boosting a certain brain protein could help slow the progression of Alzheimer’s disease, a new study has found. The ...

The Western New York Chapter of the Alzheimer’s Association will offer a free education program on recognizing and understanding Alzheimer’s disease and dementia at 10 a.m. Thursday at ...

Kearney physician Dr. Bradley Rodgers will soon offer Kisunla, the first drug proven to slow the early onset of Alzheimer’s.

The expansion will increase production of biologic active ingredients, including those for its recently approved treatment for early symptomatic Alzheimer's disease, Kisunla (donanemab-azbt). The ...

Leqembi and Kisunla don’t just reduce amyloid plaques that are implicated in Alzheimer’s disease. According to new research, ...

Eli Lilly said it will spend $1.8 billion to boost production in Ireland of its popular diabetes and weight-loss drugs, along with ingredients for its recently approved Alzheimer’s treatment, Kisunla.

Two monoclonal antibody treatments to slow Alzheimer's disease, lecanemab (Leqembi) and donanemab (Kisunla), have been ...

Researchers have discovered that Alzheimer's drugs Leqembi and Kisunla boost levels of a healthy form of protein in the brain, even as they reduce its more toxic form.